Shift From Surrogate End Point to Outcome Trials: Implications for Cardiovascular Safety Assessment in Development Programs for Antidiabetic Drugs

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|91|3|514-520

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.91, Iss.3, 2012-03, pp. : 514-520

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical trials and surrogate end points: lessons from the ENHANCE trial

By Farmer John Alan  

Future Lipidology, Vol. 3, Iss. 4, 2008-08 ,pp. : 353-357

Future Medicine

Access to resources Recommend Favorite

The kidney and cardiovascular outcome trials

By  

JOURNAL OF DIABETES, Vol. 10, Iss. 2, 2018-02 ,pp. : 88-89

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessing a composite end point for new tocolytics in clinical trials: Data from 4 US integrated delivery networks

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 27, Iss. 2, 2018-02 ,pp. : 213-220

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 18, Iss. 10, 2016-10 ,pp. : 1034-1040

John Wiley & Sons Inc

Access to resources Recommend Favorite

Surrogate Endpoints for the Assessment of Efficacy in Venous Thromboembolism Treatment Trials

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 3, 2004-11 ,pp. : 127-130

Karger

Access to resources Recommend Favorite